Stock A041830 INBODY CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings InBody Co.,Ltd

Equities

A041830

KR7041830001

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
25,500 KRW -0.39% Intraday chart for InBody Co.,Ltd -1.92% +0.59%
2023 InBody Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2022 InBody Releases BPBIO 220 and BPBIO 250 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Its low valuation, with P/E ratio at 8.54 and 7.19 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company has a low valuation given the cash flows generated by its activity.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
INBODY CO.,LTD Stock InBody Co.,Ltd
+0.59% 241M -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+1.36% 204B
B
DANAHER CORPORATION Stock Danaher Corporation
+3.67% 178B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+30.06% 154B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+31.57% 112B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.79% 64.32B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+20.05% 54.88B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-2.27% 47.24B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-9.21% 36.8B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
-0.74% 35.26B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. A041830 Stock
  4. Ratings InBody Co.,Ltd